These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 22255027)

  • 21. A novel non-phosphorylated potential antitumoral peptide inhibits STAT3 biological activity.
    Dourlat J; Liu WQ; Sancier F; Edmonds T; Pamonsinlapatham P; Cruzalegui F; Garbay C
    Biochimie; 2009 Aug; 91(8):996-1002. PubMed ID: 19470402
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Structure-based design of peptidomimetic ligands of the Grb2-SH2 domain.
    Schoepfer J; Gay B; Caravatti G; Garcia-Echeverria C; Fretz H; Rahuel J; Furet P
    Bioorg Med Chem Lett; 1998 Oct; 8(20):2865-70. PubMed ID: 9873638
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Selective Inhibition of STAT3 with Respect to STAT1: Insights from Molecular Dynamics and Ensemble Docking Simulations.
    Yesylevskyy SO; Ramseyer C; Pudlo M; Pallandre JR; Borg C
    J Chem Inf Model; 2016 Aug; 56(8):1588-96. PubMed ID: 27479469
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Inhibiting aberrant signal transducer and activator of transcription protein activation with tetrapodal, small molecule Src homology 2 domain binders: promising agents against multiple myeloma.
    Page BD; Croucher DC; Li ZH; Haftchenary S; Jimenez-Zepeda VH; Atkinson J; Spagnuolo PA; Wong YL; Colaguori R; Lewis AM; Schimmer AD; Trudel S; Gunning PT
    J Med Chem; 2013 Sep; 56(18):7190-200. PubMed ID: 23968501
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cytosolic delivery of peptidic STAT3 SH2 domain inhibitors.
    Cerulli RA; Shehaj L; Tosic I; Jiang K; Wang J; Frank DA; Kritzer JA
    Bioorg Med Chem; 2020 Jun; 28(12):115542. PubMed ID: 32503696
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Evaluation of quantitative assays for the identification of direct signal transducer and activator of transcription 3 (STAT3) inhibitors.
    Furtek SL; Matheson CJ; Backos DS; Reigan P
    Oncotarget; 2016 Nov; 7(47):77998-78008. PubMed ID: 27793003
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Allosteric regulation in STAT3 interdomains is mediated by a rigid core: SH2 domain regulation by CCD in D170A variant.
    Zhao T; Karki N; Zoltowski BD; Matthews DA
    PLoS Comput Biol; 2022 Dec; 18(12):e1010794. PubMed ID: 36542668
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Dual-inhibitors of STAT5 and STAT3: studies from molecular docking and molecular dynamics simulations.
    Shao S; Yu R; Yu Y; Li Y
    J Mol Model; 2014 Aug; 20(8):2399. PubMed ID: 25098340
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Inhibition of Stat3 by cell-permeable peptidomimetic prodrugs targeted to its SH2 domain.
    McMurray JS; Mandal PK; Liao WS; Ren Z; Chen X
    Adv Exp Med Biol; 2009; 611():545-6. PubMed ID: 19400306
    [No Abstract]   [Full Text] [Related]  

  • 30. Interaction of a small molecule Natura-α and STAT3-SH2 domain to block Y705 phosphorylation and inhibit lupus nephritis.
    Chiao JW; Melikian M; Han L; Xue C; Tsao A; Wang L; Mencher SK; Fallon J; Solangi K; Bertho G; Wang LG
    Biochem Pharmacol; 2016 Jan; 99():123-31. PubMed ID: 26612419
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Macrocyclization in the design of Grb2 SH2 domain-binding ligands exhibiting high potency in whole-cell systems.
    Wei CQ; Gao Y; Lee K; Guo R; Li B; Zhang M; Yang D; Burke TR
    J Med Chem; 2003 Jan; 46(2):244-54. PubMed ID: 12519063
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Design, synthesis, and in vitro characterization of novel hybrid peptidomimetic inhibitors of STAT3 protein.
    Shahani VM; Yue P; Fletcher S; Sharmeen S; Sukhai MA; Luu DP; Zhang X; Sun H; Zhao W; Schimmer AD; Turkson J; Gunning PT
    Bioorg Med Chem; 2011 Mar; 19(5):1823-38. PubMed ID: 21216604
    [TBL] [Abstract][Full Text] [Related]  

  • 33. In silico simulations of STAT1 and STAT3 inhibitors predict SH2 domain cross-binding specificity.
    Szelag M; Sikorski K; Czerwoniec A; Szatkowska K; Wesoly J; Bluyssen HA
    Eur J Pharmacol; 2013 Nov; 720(1-3):38-48. PubMed ID: 24211327
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Identification of New Shikonin Derivatives as Antitumor Agents Targeting STAT3 SH2 Domain.
    Qiu HY; Zhu X; Luo YL; Lin HY; Tang CY; Qi JL; Pang YJ; Yang RW; Lu GH; Wang XM; Yang YH
    Sci Rep; 2017 Jun; 7(1):2863. PubMed ID: 28588262
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Novel synthetic bisindolylmaleimide alkaloids inhibit STAT3 activation by binding to the SH2 domain and suppress breast xenograft tumor growth.
    Li X; Ma H; Li L; Chen Y; Sun X; Dong Z; Liu JY; Zhu W; Zhang JT
    Oncogene; 2018 May; 37(18):2469-2480. PubMed ID: 29456240
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Utilization of a beta-aminophosphotyrosyl mimetic in the design and synthesis of macrocyclic Grb2 SH2 domain-binding peptides.
    Lee K; Zhang M; Liu H; Yang D; Burke TR
    J Med Chem; 2003 Jun; 46(13):2621-30. PubMed ID: 12801226
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Towards the Inhibition of Protein-Protein Interactions (PPIs) in STAT3: Insights into a New Class of Benzothiadiazole Derivatives.
    Mori M; Gilardoni E; Regazzoni L; Pedretti A; Colombo D; Parkinson G; Asai A; Meneghetti F; Villa S; Gelain A
    Molecules; 2020 Jul; 25(15):. PubMed ID: 32752073
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Conformational analysis of cyclic hexapeptides designed as constrained ligands for the SH2 domain of the p85 subunit of phosphatidylinositol-3-OH kinase.
    Barchi JJ; Nomizu M; Otaka A; Roller PP; Burke TR
    Biopolymers; 1996 Feb; 38(2):191-208. PubMed ID: 8589253
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Inhibition of Grb2 SH2 domain binding by non-phosphate-containing ligands. 2. 4-(2-Malonyl)phenylalanine as a potent phosphotyrosyl mimetic.
    Gao Y; Luo J; Yao ZJ; Guo R; Zou H; Kelley J; Voigt JH; Yang D; Burke TR
    J Med Chem; 2000 Mar; 43(5):911-20. PubMed ID: 10715157
    [TBL] [Abstract][Full Text] [Related]  

  • 40. L-O-(2-malonyl)tyrosine: a new phosphotyrosyl mimetic for the preparation of Src homology 2 domain inhibitory peptides.
    Ye B; Akamatsu M; Shoelson SE; Wolf G; Giorgetti-Peraldi S; Yan X; Roller PP; Burke TR
    J Med Chem; 1995 Oct; 38(21):4270-5. PubMed ID: 7473554
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.